Please ensure Javascript is enabled for purposes of website accessibility

Why KemPharm Stock Sank Today

By Keith Speights - Jun 18, 2021 at 4:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors reacted negatively to the company's warrant exchange.

What happened

Shares of KemPharm (KMPH 4.71%) were sinking 12.6% as of 3:33 p.m. EDT on Friday. The big drop came after the drugmaker announced the exercise of existing warrants and the issuance of new warrants.

So what

A warrant gives the right to buy a stock at a set price and set date. In KemPharm's latest transaction, holders with warrants that could have been exercised for nearly 6.2 million shares received a new deal. They received cash in exchange for a commitment from the company to issue new warrants.

These new warrants will allow the purchase of up to 1,529,379 KemPharm shares. They will give the holders the right to buy the stock at $16.50 per share. The warrants expire on Dec. 31, 2026.

Red line with an arrow trending down in front of a $100 bill.

Image source: Getty Images.

Investors didn't react favorably because the transaction means more dilution is on the way. However, the deal will generate close to $39.1 million in gross proceeds for KemPharm.

Now what

KemPharm expects to launch Azstarys in treating attention deficit hyperactivity disorder (ADHD) within the next few months. The drug won Food and Drug Administration approval in March. Its stock is scheduled to be added to the Russell 2000 and Russell 3000 indexes effective June 28. These milestones could serve as positive catalysts for the biotech stock.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

KemPharm, Inc. Stock Quote
KemPharm, Inc.
$6.44 (4.71%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.